UBS Maintains Neutral on Iovance Biotherapeutics, Raises Price Target to $8

Benzinga · 2d ago
UBS analyst David Dai maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Neutral and raises the price target from $7 to $8.